PIK3CA and breast carcinoma: Alpelisib may be used more effectively than other drugs in CMT patients when there is a concurrent occurrence of a PIK3CA mutation and a malignant diagnosis, similar to its use to prevent recurrence and metastasis in metastatic human breast cancers with PIK3CA-mutations.